PARP1 and melanoma: Several studies have also identified utility in combinatory PARP inhibition (niraparib or talazoparib) and radiotherapy, via the induction of G2/M arrest and subsequent cell death, suggesting that PARP inhibition can sensitize melanoma to varying therapeutic modalities [49,56].